secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001213900-25-111045
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive Therapeutics increases ATM offering capacity from $50M to $100M
-------------------------------------------------------------------------

- Amendment No. 1 to Sales Agreement raises aggregate offering price limit from $50M to $100M.
- Sales agent remains Guggenheim Securities, LLC; shares sold at market prices under Rule 415.
- Company filed a prospectus supplement with the SEC on November 14, 2025, covering the increase.
- Legal opinion on share validity from Sheppard Mullin filed as Exhibit 5.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025111045/0001213900-25-111045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025111045/ea0265675-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-111045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer